Endonovo Therapeutics Inc. ENDV Archives - Page 4 of 5

FridayJul 19, 2019 12:45 pm

Endonovo Therapeutics Inc. (ENDV) Delivering Safe Patient Recovery Tech as Alternative to Traditional Opioid Pain Management Solutions

While the post-operative pain management market is anticipated to grow, the U.S. is looking for alternatives to traditional opioid administration Endonovo has alternative technologies that allow for effective pain and swelling management, bringing down the need for the administration of opioids Endonovo announced the rollout of its therapeutic device in hospitals and pain management centers across the U.S.; it’s planning to be in the evaluation stage with 600 hospitals over the course of 18 months The global post-operative pain management market is anticipated to grow at a CAGR of 5.4 percent through 2023, with an increasing number of surgeries worldwide…

MondayJul 15, 2019 10:40 am

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Appoints Dr. Peter Novak to Scientific Advisory Board

Endonovo Therapeutics Inc. (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(TM) therapeutic devices, this morning announced its appointment of Peter Novak, M.D., Ph.D., to its scientific advisory board. According to the update, Novak is a board-certified neurologist and autonomic specialist who serves as the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. In addition, he is a member of the American Academy of Neurology, the American Autonomic Society and the Autonomic Board of United Council for Neurologic Subspecialties. “The Endonovo team is delighted to welcome Dr. Novak to the Scientific Board,”…

TuesdayJul 09, 2019 3:28 pm

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Adds National Leader to Scientific Advisory Board

Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company, recently named Dr. Steven Levin, M.D., to its scientific advisory board. An article further discussing the appointment reads, “‘Dr. Levin’s vast experience with novel therapies in the anesthesiology and pain-management field, as well as his strong research interest to improve clinical practice in pain management, will be valuable scientific additions to Endonovo,’ Alan Collier, CEO of Endonovo Therapeutics, said in a news release (http://ibn.fm/UFbNO). ‘As a leader in the field of pain management, Steven will contribute valuable knowledge and expertise as we move our programs forward.’ . . . Levin’s membership in…

MondayJul 08, 2019 11:20 am

Endonovo Therapeutics Inc. (ENDV) Offers Non-Narcotic, Non-Invasive Power of SofPulse to Help Patients Recover More Quickly

Proprietary bioelectronic devices developed by Endonovo Therapeutics target patient pain and inflammation while aiding wound recovery SofPulse® safely decreases pain by reducing edema (swelling), which decreases the need for prescription pain medications Endonovo’s wearable device can be used to address an array of medical conditions and is FDA-cleared for treating post-operative pain and edema in soft tissue Endonovo Therapeutics Inc. (OTCQB: ENDV) is transforming the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver Endonovo’s Electroceutical™ Therapy. Targeting inflammatory conditions in vital organs and peripheral tissues, Endonovo’s SofPulse® is clinically proven to significantly speed the recovery…

WednesdayJul 03, 2019 12:10 pm

Endonovo Therapeutics Inc. (ENDV) Appoints National Leader in Pain Management to Scientific Advisory Board

Appointment of Dr. Steven Levin of Johns Hopkins University to Endonovo’s scientific advisory board is expected to help facilitate the introduction of Endonovo’s non-invasive bio-electrical medical devices to hospitals and clinics The global wearable medical devices market is expected to grow to nearly $67 billion by 2026 at a CAGR of 26.1 percent Endonovo holds 27 patents and numerous trademarks for several proprietary technologies and medical devices Endonovo Therapeutics Inc. (OTCQB: ENDV), a commercial-stage developer of non-invasive electroceutical therapeutic devices, has appointed Dr. Steven Levin, M.D., a national leader in the field of pain management, to its scientific advisory board. Levin…

TuesdayJul 02, 2019 3:18 pm

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Details National Rollout of Natural, Safe Alternative to Opioids

As part of its goal to reduce post-operative drug dependence, innovative biotechnology company Endonovo Therapeutics (OTCQB: ENDV) recently revealed plans to get its flagship SofPulse Therapy Device into 600 hospitals within the next 18 months. An article further discussing the company reads, “On June 13, the company detailed its initial strategy for a national rollout of its SofPulse targeted pulsed electromagnetic field (tPEMF) therapy device to hospitals throughout the United States. According to the company’s news release, Endonovo plans to be in the evaluation stage with 600 hospitals within the next 18 months, employing 300 sales representatives (http://ibn.fm/gAHv2). . .…

WednesdayJun 26, 2019 3:15 pm

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Positioned to Take Advantage of Expanding Wearable Medical Devices Market

Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company, is poised to profit as the wearable medical devices market is forecasted to rapidly increase over the coming years. An article discussing the company reads, “The global wearable medical devices market is anticipated to grow to $66.8 billion by 2026, a Grandview Research report published in April 2019 suggests (http://ibn.fm/AzXnV). The market is forecast to expand at a CAGR of 26.1% over the period, with several factors contributing to the growth. . . . Increased health awareness and a better understanding of the need for constant monitoring will both help the market expand.…

FridayJun 21, 2019 11:01 am

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Appoints Leader in Field of Pain Management to its Scientific Advisory Board

Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company, this morning announced the appointment of Steven Levin, M.D., to its scientific advisory board. Per the update, Dr. Levin will assist Endonovo to facilitate the SofPulse(R) introduction to healthcare facilities and further develop the Electroceutical(TM) devices pipeline. “Dr. Levin's vast experience with novel therapies in the anesthesiology and pain management field, as well as his strong research interest to improve clinical practice in pain management, will be valuable scientific additions to Endonovo,” ENDV CEO Alan Collier said in the news release. “As a leader in the field of pain management, Steven will…

TuesdayJun 18, 2019 11:31 am

Endonovo Therapeutics Inc. (ENDV) Announces Nationwide Strategy as it Promotes Non-Drug Alternative to Opioid Addiction Crisis

Endonovo Therapeutics is developing bioelectronic devices that target patient pain, inflammation and wound recovery The company intends to get its flagship SofPulse device into 600 hospitals within the next 18 months as part of its bid to reduce post-operative drug dependence Drug dependence is regarded as a major contributor to a global opioid epidemic that has driven advocacy for less harmful pain drugs, increased governmental funding and new sentencing protocols for drug-related crimes The U.S. government has spent $2.4 billion during the past two years on addiction intervention amid statistics showing pain-killer death totals in the tens of thousands each…

MondayJun 17, 2019 10:32 am

Endonovo Therapeutics Inc. (ENDV) Positioned to Benefit as Wearable Medical Devices Market Projected to Reach $66.8 Billion by 2026

An aging Western population and the prevalence of chronic diseases are expected to contribute to the massive growth of the wearable medical devices market in the years to come Companies like Endonovo Therapeutics are primed to benefit from the growth opportunities due to innovative developments that are currently in the clinical stages Endonovo’s wearable medical device can be used to address an array of medical conditions; it promotes faster post-surgery and wound healing and can also effectively manage inflammatory processes in the body The global wearable medical devices market is anticipated to grow to $66.8 billion by 2026, a Grandview…

Site Search

Company Search

Tag: Endonovo Therapeutics Inc. ENDV